U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H26N2O2.2ClH
Molecular Weight 459.408
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEDIBAZINE DIHYDROCHLORIDE

SMILES

Cl.Cl.C(N1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC5=C(OCO5)C=C4

InChI

InChIKey=NABGGBAFLGQEJP-UHFFFAOYSA-N
InChI=1S/C25H26N2O2.2ClH/c1-3-7-21(8-4-1)25(22-9-5-2-6-10-22)27-15-13-26(14-16-27)18-20-11-12-23-24(17-20)29-19-28-23;;/h1-12,17,25H,13-16,18-19H2;2*1H

HIDE SMILES / InChI

Description

Medibazine (Vialibran) is a piperazine derivative. Medibazine is a coronary vasodilating agent. Although several non-controlled trials report favorable results with angina patients this medication certainly does not provide any outstanding results.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
PubMed

PubMed

TitleDatePubMed
[Cardiac anti-arrhythmic effect of various N-substituted piperazine derivatives with respect to aconitine in the rat].
1979
Angina drug trial: a comparison of the clinical use of vialibran and iproveratril.
1967-11-25
Patents

Patents

US3119826
3
Name Type Language
VIALIBRAN
Preferred Name English
MEDIBAZINE DIHYDROCHLORIDE
Common Name English
PIPERAZINE, 1-(1,3-BENZODIOXOL-5-YLMETHYL)-4-(DIPHENYLMETHYL)-, HYDROCHLORIDE (1:2)
Systematic Name English
MEDIBAZINE DIHYDROCHLORIDE [MI]
Common Name English
Code System Code Type Description
PUBCHEM
13861295
Created by admin on Mon Mar 31 21:52:55 GMT 2025 , Edited by admin on Mon Mar 31 21:52:55 GMT 2025
PRIMARY
MERCK INDEX
m301
Created by admin on Mon Mar 31 21:52:55 GMT 2025 , Edited by admin on Mon Mar 31 21:52:55 GMT 2025
PRIMARY
CAS
96588-03-3
Created by admin on Mon Mar 31 21:52:55 GMT 2025 , Edited by admin on Mon Mar 31 21:52:55 GMT 2025
PRIMARY
FDA UNII
6NRF3LXS7J
Created by admin on Mon Mar 31 21:52:55 GMT 2025 , Edited by admin on Mon Mar 31 21:52:55 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of MEDIBAZINE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966